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ReviewThe process of cellular senescence was first described 
in a seminal study by Hayflick and Moorhead (1961) in 
which they observed that normal human fibroblasts 
were able to enter a state of irreversible growth arrest 
after serial cultivation in vitro; meanwhile cancer cells did 
not enter this growth arrest state and proliferated indefi-
nitely. Hayflick and Moorhead (1961) presciently hypoth-
esized the existence of cellular factors, whose loss 
through consecutive cell divisions limited the prolifera-
tion of normal cells. They went on to speculate that this 
“stopwatch” could be behind the process of organismal 
aging. Today, cellular senescence is considered a stress 
response triggered by a number of “counting mecha-
nisms,” such as telomere shortening, that are increas-
ingly well understood at the molecular level. Importantly, 
the mechanisms underlying cellular senescence are 
involved in protection against cancer and also may be 
involved in organismal aging. It is important to empha-
size here that although senescent cells 
in vitro may remain viable essentially 
indefinitely—albeit incapable of prolif-
eration—the situation in vivo may be 
more complex. There are examples of 
in vivo senescent cells that may reside 
for years in the organism, such as the 
senescent melanocytes of moles or nevi 
(Michaloglou et al., 2005), and there 
are also examples of senescent cells 
that are rapidly removed by phago-
cytic cells, as in the case of senescent 
tumor cells in liver carcinomas (Xue et 
al., 2007). In the case of physiological 
aging, the increase in senescent cells 
is measurable but modest (Dimri et al., 
1995). However, senescence may con-
tribute to aging not only by net accu-
mulation of senescent cells in tissues, 
but also by limiting the regenerative 
potential of stem cell pools. These two 
mechanisms—namely, accumulation 
of senescent cells and loss of stem cell 
function—probably contribute to aging 
simultaneously. Below, we review the molecular biology 
of the three main “Hayflick factors” (Figure 1; telomere 
loss, the accumulation of DNA damage, and derepres-
sion of the INK4a/ARF locus) and discuss their role in 
cancer protection and the current understanding of their 
involvement in aging.
Recording Cell Divisions by Telomere Loss
Studies of telomere length regulation provided the first 
molecular mechanism capable of counting cell divisions 
and implementing cell cycle arrest (Harley et al., 1990). 
Telomeres consist of repetitive DNA elements at the end 
of linear chromosomes that protect the DNA ends from 
degradation and recombination (Chan et al., 2001; de 
Lange, 2005). Due to the intrinsic inability of the replica-
tion machinery to copy the ends of linear molecules, telo-
meres become progressively shorter with every round of 
cell division (Blasco, 2005). Eventually, telomeres reach a 
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Cellular senescence, a state of irreversible growth arrest, can be triggered by multiple 
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locus, and DNA damage. Together these mechanisms limit excessive or aberrant cellular 
proliferation, and so the state of senescence protects against the development of cancer. 
Recent evidence suggests that cellular senescence also may be involved in aging.
Figure 1. “Hayflick Factors” Record the Proliferative History of Cells and Tissues
The three best-known Hayflick factors—telomere shortening, accumulation of DNA damage, 
and derepression of the INK4a/ARF locus—are summarized together with their main effec-
tors, the tumor suppressors p53 and retinoblastoma (Rb).Cell 130, July 27, 2007 ©2007 Elsevier Inc. 223
critically short length, behaving as double-stranded DNA 
breaks that activate the p53 tumor suppressor protein 
resulting in telomere-initiated senescence or apoptosis 
(de Lange, 2005; von Zglinicki et al., 2005). Telomerase 
is a ribonucleoprotein with DNA polymerase activity that 
elongates telomeres (Greider and Blackburn, 1985), but 
its level of activity in most adult tissues is not sufficient 
to compensate for the progressive telomere attrition 
that occurs with aging (Collins and Mitchell, 2002). The 
generation of telomerase-deficient mice demonstrated 
that telomerase is the main cellular activity responsible 
for maintaining telomere length (Blasco et al., 1997). 
Importantly, in the case of in vitro cultured cells, ecto-
pic expression of telomerase was sufficient to prevent 
telomere shortening, and this resulted in immortalization 
of human fibroblasts, thus formally demonstrating that 
telomere exhaustion is a critical factor leading to cellular 
senescence (Bodnar et al., 1998).
The Telomere Clock in Cancer Protection
The telomere clock limits not only the proliferation of nor-
mal noncancerous cells, but also the proliferation of those 
cells that are already on the road to neoplastic transfor-
mation. This is best illustrated by the fact that essentially 
all human cancers have acquired mechanisms to maintain 
telomeres, generally through the expression of high levels 
of telomerase (Stewart and Weinberg, 2006). Exceptionally, 
immortal human cell lines and tumors may maintain their 
telomeres in the absence of telomerase through a mecha-
nism known as alternative lengthening of telomeres (ALT), 
which involves homologous recombination between telo-
meres (Muntoni and Reddel, 2005). These observations in 
human cancer strongly support the concept that telomer-
ase is a tumorigenic factor that enables tumor progression. 
In agreement with this, mice deficient in telomerase activity 
are significantly resistant to cancer induced by a variety of 
genetic defects or carcinogenic treatments (Blasco, 2005). 
The two main exceptions to this general trend occur when 
lack of telomerase is combined with a deficiency in p53 
(Chin et al., 1999) or with overexpression of the telomere-
binding protein TRF2, which recruits the nuclease XPF to 
telomeres and degrades them (Blanco et al., 2007). Under 
these conditions, cells proliferate in the presence of ram-
pant chromosomal aberrations, which in turn fuels the 
development of cancer (Artandi et al., 2000).
The final cellular outcome responsible for telomere-
mediated protection against cancer involves senes-
cence and apoptosis (Kelland, 2005; Shammas et al., 
2005). Whether a cell senesces or undergoes apoptosis 
likely depends on both cell type and context. Moreover, 
preneoplastic cells are exposed not only to dysfunc-
tional short telomeres but also to other potential trig-
gers of senescence or apoptosis, such as oncogenic 
signaling. Recently, telomere-induced senescence has 
been shown to act as a tumor suppressor mechanism 
in telomerase-deficient mice expressing the oncogene 
Myc in B cells (Feldser and Greider, 2007). Short telo-
meres reduced the incidence of cancer in these animals 
even when apoptosis was blocked by overexpression of 224 Cell 130, July 27, 2007 ©2007 Elsevier Inc.the antiapoptotic protein Bcl2. Examination of the lymph 
nodes of these apoptosis-resistant mice revealed clear 
signs of senescence induction, demonstrating that telo-
mere-dependent senescence is an efficient mechanism 
to suppress cancer in vivo (Feldser and Greider, 2007).
The Telomere Clock in Aging
In humans, many studies have described an inverse cor-
relation between telomere length and age in a variety of 
tissues and between telomere length and diseases asso-
ciated with aging (Canela et al., 2007; Cawthon et al., 
2003; Ogami et al., 2004; Panossian et al., 2003). Also, 
factors that may decrease longevity, such as psychologi-
cal stress or obesity, decrease telomerase activity and 
telomere length (Epel et al., 2004; Valdes et al., 2005). 
In addition, several human premature aging syndromes, 
such as dyskeratosis congenita (DC) and aplastic anemia, 
are linked to mutations in telomerase or in proteins that 
directly affect telomerase activity and are characterized 
by a faster rate of telomere attrition with age (Mason and 
Bessler, 2004). Other premature aging syndromes, includ-
ing those produced by mutations in DNA repair proteins 
such as NBS1 (Nijmegen breakage syndrome), MRE11 
(Ataxia telangiectasia-like disorder), WRN (Werner syn-
drome), BLM (Bloom syndrome), ATM (Ataxia telangiecta-
sia), and FANC (Fanconi anemia), are also characterized 
by an accelerated rate of telomere attrition and chromo-
somal instability (reviewed in Blasco, 2005). Additionally, it 
is important to note that the rate of telomere shortening is 
accelerated by oxidative damage (von Zglinicki and Mar-
tin-Ruiz, 2005). Taking into account that aging is asso-
ciated with the accumulation of oxidative damage (see 
below), it is conceivable that telomere shortening could 
reflect not only the proliferative history of a cell, but also 
the accumulation of oxidative damage.
Further reinforcing the link between the telomere 
clock and aging, mice deficient in telomerase activ-
ity have short telomeres and age prematurely (Blasco 
et al., 1997; Lee et al., 1998). Remarkably, even the first 
generation of telomerase-deficient mice already has a 
shortened lifespan, which becomes shorter and shorter 
in subsequent generations (Garcia-Cao et al., 2006). 
Moreover, telomeres become measurably shorter in 
mice, particularly at very old ages, both in Mus spretus 
(Coviello-McLaughlin and Prowse, 1997) and in labora-
tory Mus musculus (unpublished data). Finally, mice over-
expressing telomerase are prone to developing tumors 
(Canela et al., 2004; Gonzalez-Suarez et al., 2001), thus 
precluding direct demonstration of lifespan extension 
by telomerase; nonetheless, an increase in the lifespan 
of those few telomerase transgenic mice that do not 
develop cancer has been observed (Gonzalez-Suarez 
et al., 2005). Together, these observations suggest that 
telomere biology (including telomere length, telomere 
capping, and rate of attrition) has a strong influence on 
longevity both in humans and in mice.
Conceivably, telomere-driven aging could be the 
consequence of telomere shortening in stem cell 
pools, which in turn results in tissues with a high rate of 
Figure 2. Senescence of Stem Cells and 
Committed Cells
Multiple mechanisms operate on stem cells and 
on committed cells to produce senescence. 
Telomere shortening, derepression of the INK4a/
ARF locus, and the accumulation of DNA dam-
age operate during the lifespan of the organism 
on stem cells (left side, from top to bottom), as 
well as on committed cells derived from the 
stem cells on their way to generating a differen-
tiated tissue (from left to right). The final result 
is age-dependent loss of stem cell functionality 
(represented by a thin arrow in the top right) and 
an age-dependent increase in the number of 
senescent cells in differentiated tissues (repre-
sented as blue cells). Tumors may arise at any 
point in life, but the stress signals characteristic 
of tumors will engage the senescence program. 
This tumor-specific senescence constitutes an 
important barrier to tumor progression.senescence, as well as a progressive exhaustion of the 
regenerative potential of stem cells (Figure 2). Together, 
these two factors—the accumulation of senescent 
cells and the loss of stem cell function—could result 
in impaired tissue function. Regarding the accumula-
tion of senescent cells, there are few reports examining 
the accumulation of senescent cells in vivo due to telo-
mere dysfunction. Abundant senescent cells (as mea-
sured by the widely used marker senescence-associ-
ated β-galactosidase or SAβGal) have been reported in 
the liver of telomerase null mice (Satyanarayana et al., 
2003). Independent of this study, a number of reports 
have obtained evidence for the presence of dysfunc-
tional telomeres in aged tissues. Critically short or dys-
functional telomeres can be considered a particular 
form of DNA damage and, as such, they are marked 
with phosphorylated histone H2AX (γH2AX; d'Adda 
di Fagagna et al., 2003). Based on this, dysfunctional 
telomeres have been visualized as foci of γH2AX that 
colocalize with telomeres in cultured human cells and in 
tissues of aged mice and baboons, providing a marker 
of telomere loss (d'Adda di Fagagna et al., 2003; Gar-
cia-Cao et al., 2006; Herbig et al., 2006). It should be 
noted, however, that not all the age-associated γH2AX 
foci are associated with telomeres (Sedelnikova et al., 
2004; see below). Recently, p21Cip1, a cyclin-depen-
dent kinase inhibitor activated by p53, has proved to 
be relevant in the signaling of critically short telomeres 
that leads to aging (Choudhury et al., 2007). Deletion 
of the gene encoding p21Cip1 prolongs lifespan and 
improves the general fitness of telomerase-deficient 
mice. These effects were observed in the absence 
of accelerated tumorigenesis, which contrasts with 
the situation in mice lacking p53 (Chin et al., 1999). In addition, given that p21Cip1 mediates p53-dependent 
senescence but not p53-dependent apoptosis, these 
results suggest that p53/p21Cip1-dependent senes-
cence specifically mediates the proaging effect of 
short telomeres. A more recent addition to this pathway 
has been the discovery that the DNA mismatch repair 
machinery, in particular the DNA repair factor PMS2, is 
involved in triggering proliferation arrest and aging by 
telomere loss in a process that appears to be upstream 
of p21Cip1 (Siegl-Cachedenier et al., 2007). Together, 
these observations are important because they dis-
sociate the proaging function of telomere shortening 
(PMS2- and p21Cip1-dependent) from the anticancer 
function of telomere shortening (p53-dependent but 
p21Cip1-independent).
The loss of stem cell function through telomere short-
ening has been extensively reported in a variety of tissues 
and experimental systems (Flores et al., 2006). On the 
one hand, short telomeres due to telomerase deficiency 
result in impaired stem cell functionality, defective tissue 
regeneration, and decreased tumorigenesis, while on the 
other hand telomerase overexpression has the opposite 
effects (Flores et al., 2005; Sarin et al., 2005). These find-
ings suggest that telomere length and telomerase activ-
ity are important determinants of stem cell fitness and in 
this manner may influence cancer and aging. Despite this 
suggestive evidence from genetically manipulated mice, 
it still remains to be demonstrated whether the telomere 
shortening in stem cells occurs during physiological 
aging, and whether stem cells with critically short telo-
meres undergo senescence or apoptosis in vivo.
In summary, current knowledge indicates that telo-
mere shortening is simultaneously a cancer protective 
mechanism and a proaging mechanism.Cell 130, July 27, 2007 ©2007 Elsevier Inc. 225
Recording Mitogenic Stimulation by the INK4a/
ARF Locus
The INK4a/ARF locus encodes two critical tumor sup-
pressors, p16INK4 and ARF, which, in addition to their role 
in cancer, are important inducers of cellular senescence. 
Although sharing exons, the two proteins are encoded 
in different reading frames, and as a consequence they 
do not have any amino acid homology and possess dif-
ferent molecular functions (Figure 1). Whereas p16INK4a 
is an inhibitor of the cyclin-dependent kinases CDK4 
and CDK6 and acts by imposing a G1 cell cycle arrest, 
ARF regulates p53 stability through inactivation of the 
p53-degrading ubiquitin ligase MDM2 (Gil and Peters, 
2006; Kim and Sharpless, 2006). The INK4a/ARF locus is 
normally expressed at very low levels in most tissues in 
young organisms but becomes derepressed with aging 
(Krishnamurthy et al., 2004). The epigenetic regulators 
of the Polycomb family are responsible, at least in part, 
for the low expression levels of p16INK4a and ARF under 
normal conditions in young tissues (Bracken et al., 2007; 
Jacobs et al., 1999). In addition, numerous positive and 
negative transcriptional regulators have been reported, 
most of which have turned out to have relevance in can-
cer (Gil and Peters, 2006; Kim and Sharpless, 2006; 
Sharpless, 2005).
Soon after the discovery of p16INK4a (Serrano et 
al., 1993), and in the context of the search for factors 
that could explain cellular senescence, it was observed 
that p16INK4a levels accumulated progressively with 
Figure 3. Cellular Senescence: Balancing Cancer and Aging
The main role of senescence in young/adult organisms is to provide 
cancer protection because the “damage” that senescent cells cause 
to tissues is efficiently repaired by the normal renewal processes. In 
mutant mice with severe constitutive DNA damage or DNA damage 
signaling (as in the case of permanently active p53), the rate of gener-
ation of senescent cells may outpace the renewal capacity of the stem 
cells (which themselves are also subject to constitutive DNA damage 
signaling), and tissues may age prematurely. This situation could also 
occur in old organisms.226 Cell 130, July 27, 2007 ©2007 Elsevier Inc.the proliferative history of cells in culture. In the case 
of embryonic murine fibroblasts, senescence in culture 
occurs despite having long telomeres and high levels 
of telomerase, but this telomere-independent clock is 
abrogated in cells genetically deficient in the INK4a/ARF 
locus (Serrano et al., 1996). A wealth of data have sub-
sequently supported a model in which cells in culture 
possess at least two independent clocks: one is telo-
mere dependent and mostly registers the accumulated 
number of cell divisions; the other clock is INK4a/ARF 
dependent and mainly records the exposure of cells to 
mitogenic stimulation. It is possible to cancel the INK4a/
ARF clock if culture conditions are finely tuned to avoid 
mitogenic overstimulation (Ramirez et al., 2001; Woo 
and Poon, 2004). Conversely, the INK4a/ARF clock can 
be accelerated by introducing high levels of expression 
of an oncogene, a phenomenon that has been called 
oncogene-induced senescence (Collado and Serrano, 
2006; Serrano et al., 1997). Cancer protection through 
the activation of the INK4a/ARF locus by oncogenes is 
well documented and will not be discussed here; the 
interested reader is referred to recent comprehensive 
reviews (Gil and Peters, 2006; Kim and Sharpless, 2006; 
Sharpless, 2005).
The INK4a/ARF Locus in Aging
Expression of both p16INK4a and ARF markedly 
increases with aging in the majority of rodent tissues 
(Krishnamurthy et al., 2004; Zindy et al., 1997). Studies 
performed in human tissues have also detected a clear 
age-dependent increase in the levels of p16INK4a in 
kidney and skin (Chkhotua et al., 2003; Ressler et al., 
2006). Together, these studies make p16INK4a an excel-
lent molecular marker of aging with on average a 30-fold 
induction in aged murine tissues (Krishnamurthy et al., 
2004) and a 7-fold induction in human skin (Ressler et 
al., 2006). The molecular mechanisms responsible for 
the increased expression of p16INK4a and ARF during 
aging are not completely understood. Among the many 
known transcriptional regulators of the locus, two have 
been associated to the age-dependent induction of 
p16INK4a. In particular, the levels of the transcriptional 
factor Ets1, which is a positive regulator of p16INK4a 
(Ohtani et al., 2001), increase during mouse aging in 
parallel to the upregulation of p16INK4a (Krishnamurthy 
et al., 2004). Similarly, the levels of the Polycomb group 
member Bmi1, which is a potent repressor of p16INK4a 
(Jacobs et al., 1999), decrease with aging in human skin 
(Ressler et al., 2006). Another important mechanism that 
could link aging with p16INK4a is oxidative damage and 
the p38MAPK pathway (Iwasa et al., 2003; Wang et al., 
2002). It has been recently observed in hematopoietic 
stem cells that reactive oxygen species activate the 
expression of the INK4a/ARF locus through p38MAPK, 
and this limits the functionality of these stem cells (Ito et 
al., 2006). Since oxidative damage increases with aging, 
it is conceivable that this could contribute to the age-
dependent upregulation of the locus. Besides being a 
marker of aging, the question of whether p16INK4a is an 
effector of aging remains open. Mice with increased lev-
els of p16INK4a and ARF have a normal lifespan (Matheu 
et al., 2004), although it could be argued that in these 
mice the putative proaging effect of p16INK4a is can-
celled by an antiaging effect of ARF (see below). On the 
other hand, mice with decreased levels of p16INK4a are 
tumor prone, and this precludes the analysis of aging 
(Krimpenfort et al., 2001; Sharpless et al., 2001).
As with telomere shortening, the proaging effects 
of p16INK4a can be the combined result of the accu-
mulation of senescent cells in tissues and, perhaps of 
higher impact, the impairment of stem cell function and 
the ensuing defects in tissue regeneration (Figure 2). 
Regarding accumulation of senescent cells, it remains 
to be demonstrated that cells expressing high levels 
of p16INK4a correlate with senescent cells in aged tis-
sues. Regarding the impairment of stem cell function, 
a connection between p16INK4a and stem cell biology 
has long been suspected based on the analysis of mice 
deficient in Polycomb genes (Valk-Lingbeek et al., 2004). 
This concept has received further support by a series 
of recent papers reporting age-induced expression of 
p16INK4a in adult stem cells and its association with 
impaired tissue regeneration of the pancreatic islets, 
hematopoietic system, and neuronal progenitors (Janzen 
et al., 2006; Krishnamurthy et al., 2006; Molofsky et al., 
2006). Moreover, mice lacking p16INK4a have increased 
regeneration potential (Janzen et al., 2006; Krishnamur-
thy et al., 2006; Molofsky et al., 2006), whereas the 
opposite is true of mice with enhanced expression of 
p16INK4a (Krishnamurthy et al., 2006). Taken together, 
these observations point to p16INK4a contributing to the 
age-associated decline in tissue regeneration character-
istic of mammalian aging. High levels of p16INK4a could 
result in suboptimal proliferation of the stem cells or even 
p16INK4a-induced senescence of the stem cells. A note 
of caution is warranted due to the fact that stem cell qui-
escence is also important to provide long-term regen-
eration potential, as it has been demonstrated for the 
cell cycle inhibitor p21Cip1 (Cheng et al., 2000). In this 
context, it is formally possible that although increased 
p16INK4a levels may impair tissue regeneration in mod-
els of acute tissue damage, it may not be detrimental for 
physiological longevity, as suggested by the analysis of 
mice with increased gene dosage of INK4a/ARF (Matheu 
et al., 2004). Recently, genetic variants in the INK4a/ARF 
locus have been linked to various age-associated dis-
eases, including general frailty, heart failure, and type 
2 diabetes (Helgadottir et al., 2007; McPherson et al., 
2007; Melzer et al., 2007; Saxena et al., 2007; Scott et 
al., 2007; Zeggini et al., 2007). Much may be clarified 
by ascertaining whether these variants have increased 
or decreased expression of INK4a/ARF and how they 
behave in response to aging or mitogenic stimulation. An 
important question that remains to be elucidated is the 
precise mechanism responsible for the derepression of 
the INK4a/ARF locus in stem cells. An attractive hypoth-
esis is that the derepression of the INK4a/ARF locus is intrinsically linked to the proliferation of stem cells and 
therefore is developmentally programmed to increase 
during aging.
In summary, the derepression of the INK4a/ARF locus 
is one of the main barriers to the outgrowth of cancer 
cells and likely contributes to aging in normal tissues.
DNA Damage
It is well established that DNA damage, in its multiple 
forms, contributes to the development of cancer. There-
fore, we will focus here on the relation between DNA dam-
age and aging. Early studies using in vitro cultured cells 
showed that the infliction of various forms of DNA dam-
age triggers senescence (Parrinello et al., 2003; te Poele 
et al., 2002). Recent data suggest that this link could be 
more profound and that DNA damage could be a com-
mon causative agent underlying different forms of cellu-
lar senescence, including not only telomere dysfunction 
(see above), but also oncogene-induced senescence 
(Bartkova et al., 2006; d’Adda di Fagagna et al., 2003; Di 
Micco et al., 2006). Organismal aging is accompanied by 
significant increases in DNA mutations (Vijg, 2000), DNA 
oxidation (Hamilton et al., 2001), chromosome losses 
(Rehen et al., 2005; Weaver et al., 2007), and telomere-
independent γH2AX foci (Sedelnikova et al., 2004). These 
and other observations have prompted researchers to 
consider DNA damage and DNA damage signaling as 
possible factors contributing to cellular senescence and 
to organismal aging. The age-dependent accumulation of 
DNA damage could result in the accumulation of senes-
cent cells in aged tissues, and it could also diminish the 
functionality of stem cells (Figure 2).
The impact of particular DNA repair defects on cancer 
and aging has been the topic of excellent and compre-
hensive reviews (for example see Lombard et al., 2005). 
The numerous mouse models described with defects in 
DNA repair present a variety of phenotypes. Some are 
dramatically cancer prone (e.g., ATM null mice; Barlow 
et al., 1996) whereas others are minimally affected in 
their cancer susceptibility (e.g., Ku80 null mice; Lim et 
al., 2000); similarly, some age prematurely (e.g., ERCC1 
null mice; Niedernhofer et al., 2006), whereas others do 
not; and, finally, the two phenotypes may or may not go 
together and may or may not correlate with premature 
cell senescence (reviewed in Lombard et al., 2005). At 
present, we lack a unified model to explain cancer and 
aging in all the available mouse models deficient in DNA 
repair, and this will most likely require a deeper under-
standing of the physiological consequences of each 
particular mutation. Nonetheless, we note some general 
tendencies. Those mutations impairing DNA damage 
signaling, but not DNA damage repair per se, such as 
ATM or Rad50, accumulate genomic instability because 
of their failure to notify the cell of DNA damage. This 
accumulation of “unnoticed” genomic instability results 
in increased propensity to cancer, whereas aging is not 
affected. On the other hand, those mutations that do not 
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stability (such as ERCC1 null mice, BRCA1-hypomorphic 
mice, or ZMPSTE24 null mice; Cao et al., 2003; Nie-
dernhofer et al., 2006; Varela et al., 2005) accumulate 
massive DNA damage that triggers strong protective 
responses that lead to premature aging in the absence 
of cancer. A consistent observation in many of the latter 
mouse models with constitutive high levels of DNA dam-
age and premature aging is the fact that the premature 
aging is partially relieved by p53 deficiency, arguing that 
this phenotype is triggered as a consequence of the sig-
naling of the damage rather than by the damage itself 
(Ferguson and Alt, 2001).
The existence of mutant mice that are deficient in DNA 
repair exhibiting premature senescence and progeroid 
phenotypes argues for the involvement of DNA damage-
induced senescence in the process of aging. However, 
as a note of caution, it should be borne in mind that all of 
the above-mentioned mouse models have massive DNA 
damage that compromises cellular viability and, impor-
tantly, require an abnormally high level of cell renewal that 
could lead to loss of stem cell functionality (Figure 3). In 
our opinion, we still lack direct proof implicating physi-
ological levels of DNA damage as a causative agent of 
aging. This would be clarified, for example, if mice with 
increased DNA damage repair age more slowly.
The Impact of p53 in Aging
The analysis of the effect of p53 in aging has revealed a 
dual role that seems to depend on the intensity of p53 
activity. Mice genetically manipulated to express con-
stitutively active mutant p53 have greater protection 
against tumor development than wild-type mice, while 
at the same time they show signs of premature aging 
(Maier et al., 2004; Tyner et al., 2002). In contrast, mouse 
models of increased wild-type p53 activity do not pres-
ent premature aging. In particular, super-p53 mice, car-
rying an extra copy of the entire p53 gene, and thus 
under the control of its natural regulatory sequences, 
exhibit increased cancer protection while displaying 
normal longevity and overall fitness (Garcia-Cao et al., 
2002). Concurring with these results, mice with a hypo-
morphic MDM2 allele, the major negative regulator of 
p53, present stronger p53-mediated activities that result 
in enhanced cancer protection without affecting aging 
(Mendrysa et al., 2006). An additional mouse model, 
super-INK4a/ARF mice, carrying an extra copy of the 
entire INK4a/ARF locus (being ARF an activator of p53), 
further supports the feasibility of getting extra cancer 
protection without the undesirable side effects of aging 
(Matheu et al., 2004). Moreover, increased p53 activity 
in super-p53 mice decreases the amount of telomere-
damaged cells in aged mice (Garcia-Cao et al., 2006). 
Finally, in agreement with the antioxidant function of p53 
(Sablina et al., 2005), increased activity of p53 by combi-
nation of extra gene dosage of p53 and ARF decreases 
the amount of oxidative damage in aged mice and delays 
aging (Matheu et al., 2007). Together, these observations 
indicate that the main role of p53 is to eliminate dam-228 Cell 130, July 27, 2007 ©2007 Elsevier Inc.aged cells, either by triggering their self-destruction (for 
example, by inducing apoptosis) or by pulling them out 
of the proliferative pool (by inducing senescence). We 
propose that under normal or moderate levels of dam-
age, such as during physiological aging, the elimina-
tion of damage by p53 has a net antiaging effect that 
compensates for the possible proaging consequences 
of p53-dependent apoptosis or senescence. In contrast, 
uncontrolled activity of p53 or the presence of massive 
DNA damage, as in some of the DNA repair mutants 
mentioned above, results in excessive elimination of 
cells by p53 that exhausts the capacity of tissue regen-
eration leading to premature aging (Figure 3).
Senescence and Cancer
The antiproliferative power of the senescence response 
clearly places this process as a plausible tumor sup-
pressor mechanism. Early on, senescence was found 
to be mediated by the two main tumor suppressor 
pathways of the cell, the ARF/p53 and the INK4a/RB 
pathways (see Figure 1; Gil and Peters, 2006; Kim and 
Sharpless, 2006). The demonstration of a senescent-
like arrest mediated by p53 and p16INK4a after ectopic 
expression of oncogenic Ras in normal primary cells 
introduced the concept of oncogene-induced senes-
cence as a mechanism to restrain the growth of poten-
tially dangerous cells (Serrano et al., 1997). Loss of these 
tumor suppressors is essential for achieving oncogenic 
transformation of human cells in vitro (Hahn and Wein-
berg, 2002), and indeed these pathways are frequently 
disrupted in human cancer cells (Gil and Peters, 2006; 
Kim and Sharpless, 2006). An ongoing debate concerns 
the relative importance of ARF and p53 in oncogene-
induced senescence. In vivo evidence using genetically 
manipulated mice indicates that ARF is the critical sen-
sor that activates p53 during tumorigenesis in response 
to oncogenic signals (Christophorou et al., 2006; Efeyan 
et al., 2006). In contrast, other investigators using cul-
tured human fibroblasts have concluded that the critical 
mediator that activates p53 in response to oncogenic 
signaling is the DNA damage signaling cascade trig-
gered by the aberrant firing of replication origins (Bart-
kova et al., 2006; Di Micco et al., 2006; Mallette et al., 
2007). This apparent conflict may reflect an intrinsic 
difference between human and mouse cells, or it could 
simply be due to differences in the experimental models 
employed.
The identification of a senescent response in vivo 
after oncogenic activation was reported only recently. 
Taking advantage of DNA microarrays to obtain the 
gene expression profiles of senescent cells, we identi-
fied markers of senescence that could then be used in 
histological sections (Collado et al., 2005). We observed 
that premalignant lesions in the lung (which developed 
in a conditional knockin mouse model of oncogenic K-
RasV12) contained abundant senescent cells, whereas 
lung adenocarcinomas were almost completely devoid 
of cells positive for markers of oncogene-induced senes-
cence. These results have been extended to Raf, a cru-
cial downstream effector for Ras-induced senescence, 
through the generation of a conditional BRAFV600E 
knockin mouse model (Dankort et al., 2007). Further 
experimental evidence for the occurrence of senescence 
during tumor progression has been independently pro-
vided by several groups. In humans, senescent cells 
were identified in benign lesions of the skin carrying 
oncogenic mutant BRAF (BRAFE600; Michaloglou et 
al., 2005); in neurofibromas from NF1 mutant patients, 
a genetic defect that leads to constitutively high levels 
of Ras activity (Courtois-Cox et al., 2006); and in benign 
lesions of the prostate (Chen et al., 2005). In mice, abun-
dant senescent cells were identified in benign lesions of 
the prostate of mice lacking the tumor suppressor PTEN 
(Chen et al., 2005), in melanocytic lesions of UV-irradi-
ated HGF/SF-transgenic mice (Ha et al., 2007), in lym-
phocytes and in the mammary gland from N-Ras trans-
genic mice (Braig et al., 2005; Sarkisian et al., 2007), 
and in hyperplasias of the pituitary gland of mice with 
deregulated E2F activity (Lazzerini Denchi et al., 2005). 
More importantly, genetic manipulations canceling the 
senescence response led to full-blown malignancy. 
Prostates from mice lacking PTEN developed adeno-
carcinomas when combined with p53 deficiency (Chen 
et al., 2005). Similarly, transgenic N-Ras animals devel-
oped malignant lymphoma after deletion of Suv39H1, a 
gene coding for a histone H3 lysine 9 methyl-transferase 
believed to be involved in the de novo formation of silent 
heterochromatin that takes part in senescence (Braig 
et al., 2005). Recently, by taking advantage of K-Ras-
transgenic mice with adjustable levels of expression, it 
has been shown that moderate levels of Ras activity trig-
ger mammary hyperplasias but are unable to produce 
tumors. Interestingly, higher levels of Ras (similar to 
those found in spontaneous tumors) trigger senescence 
and result in malignant tumors when the senescence-
inducing pathways are disrupted (Sarkisian et al., 2007). 
In summary, there is now compelling evidence to asso-
ciate senescent cells with premalignant stages of tumor 
development. These findings indicate that senescence 
restricts tumor progression and might potentially serve 
as a useful marker for tumor staging (Collado and Ser-
rano, 2006). Despite the above-described advances, it 
still remains to be rigorously examined whether senes-
cent cells in premalignant lesions share all the features 
that characterize in vitro senescent cells—in particular 
whether the proliferative arrest is irreversible. In this 
regard it is worth mentioning that some authors distin-
guish two types of senescence-like arrest in vitro—a 
reversible one mediated by p53 and an irreversible one 
mediated by the concomitant actions of the INK4a/Rb 
and p53 pathways (Beausejour et al., 2003).
Even though cancer cells have partially lost the 
capacity to signal senescence or apoptosis, these 
responses can conceivably be engaged by exogenous 
chemotherapeutic drugs. Many of the chemotherapeutic 
drugs currently used in the clinic or under investigation act by inflicting severe DNA damage to the tumor cell 
and correspondingly trigger cellular senescence in vitro. 
Interestingly, there is evidence that they can also trig-
ger senescence of cancer cells in real tumors, and it is 
possible that senescence could contribute to the suc-
cess of chemotherapy (Roberson et al., 2005; te Poele 
et al., 2002). In this sense, chemotherapeutic interven-
tion aimed to trigger senescence might prove effective. 
Genetic demonstration of this notion has been provided 
recently using two elegantly designed mouse mod-
els. Tumors initiated by loss of p53 can be eliminated 
by p53 restoration and, at least for some tumor types, 
such as hepatocarcinomas or soft-tissue sarcomas, 
tumor regression is achieved through senescence (Ven-
tura et al., 2007; Xue et al., 2007). This implies that the 
signals that would activate p53 to induce senescence 
might still be present in the tumor. Thus, small molecule 
inhibitors aimed at restoring normal p53 signaling could 
prove effective in controlling cancer. Significantly, tumor 
regression by senescence induced after p53 restoration 
proceeded through an innate immune response that led 
to clearance of the senescent cells (Xue et al., 2007). 
Thus, senescent cells can be cleared in vivo, at least in 
the context of tumor suppression. Whether this is also 
the case during aging remains to be investigated, and 
it would imply that the higher abundance of senescent 
cells in aged tissues (see above) reflects an increase in 
the generation of senescent cells rather than their net 
accumulation over the years. Hopefully, future research 
will clarify whether therapies that induce senescence are 
useful for treating cancer and will determine their effect 
on normal cells and in aging. 
Senescence and Aging
The association between cellular senescence and organ-
ismal aging is highly suggestive of a causal link between 
these two processes, although establishing a direct 
causative relationship is challenging. To start with, the 
factors that trigger senescence also trigger apoptosis 
and quiescence, making it difficult to dissect the con-
tribution of each of these responses to aging. An addi-
tional complexity, already mentioned at the beginning 
of this review, is that senescence may impact on aging 
through two nonexclusive and possibly concomitant 
mechanisms (Figure 2). First, accumulation of senescent 
cells in tissues may reach a point that compromises 
functionality, and, second, senescence may limit the 
regenerative potential of adult stem cells (a limitation 
that may be produced as well by quiescence or apop-
tosis of stem cells). In one extreme, aging could be pro-
duced by the net accumulation of senescent cells; in the 
other extreme, the accumulation of senescent cells per 
se could be harmless, and aging could result primarily 
from the exhaustion of the regenerative potential of stem 
cells. Finally, and in relation to the above, it remains to 
be determined whether adult stem cells undergo senes-
cence, quiescence, or apoptosis upon exhaustion of 
their proliferative potential.Cell 130, July 27, 2007 ©2007 Elsevier Inc. 229
It is an incontrovertible fact that cancer is more fre-
quent at advanced ages. The simplest explanation for 
this is that old organisms have accumulated more genetic 
and epigenetic aberrations than young organisms, but 
this does not say anything about the intrinsic suscepti-
bility (that is, apart from the accumulation of mutations) 
of young and old organisms to develop cancer. The pro-
gressive action of the Hayflick factors throughout life 
poses important questions regarding the link between 
cancer and aging. Conceivably, it could be argued that 
because the Hayflick factors become progressively 
activated with time, this should result not only in aging 
but also in cancer protection. For example, genetically 
manipulated mice with short telomeres (Blasco, 2005) 
or with higher levels of p16INK4a (Matheu et al., 2004) 
are cancer resistant. In this sense, aged organisms, by 
having shorter telomeres, higher levels of p16INK4a, or 
higher levels of DNA damage signaling to p53, should 
be more resistant to oncogene-driven proliferation than 
young organisms. According to this view, the higher 
incidence of cancer at old ages simply reflects the 
time needed for the accumulation of oncogenic muta-
tions. Alternatively, it has been observed that senes-
cent cells, in contrast to normal cells, provide a better 
milieu and stromal support for cancer cells (Krtolica et 
al., 2001). According to this notion, aged organisms are 
more cancer prone by the combination of two factors: 
the accumulation of oncogenic mutations and the favor-
able environment for cancer growth. Addressing these 
issues will be of great importance in understanding the 
link between cancer and aging.
Great progress has been made in the last few years in 
understanding how cells limit their proliferative potential 
and in linking these mechanisms to cancer protection 
and aging. Future research will clarify whether therapies 
that induce senescence are useful for cancer treatment, 
and determine their effect on aging. Conversely, treat-
ments that inhibit senescence in healthy individuals 
might slow aspects of aging.
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